幹細胞から乳がん細胞へのエクソソームの移転は,治療抵抗性の経路を調節する
Mirjam C Boelens1, Tony J Wu1, Barzin Y Nabet1
1Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Cell
|November 24, 2014
まとめ
ストロマ細胞は乳がん細胞と通信し,化学療法と放射線に対する耐性を促進します. このクロスストークは,エクソソームが抗ウイルス信号伝達とNOTCH3経路を活性化し,治療に抵抗する腫瘍の成長につながります.
科学分野:
- 腫瘍学 腫瘍学
- 細胞生物学 細胞生物学
- 免疫学 免疫学とは
背景:
- ストロマ・ガン細胞の相互作用は,腫瘍の進行と治療結果に大きな影響を与えます.
- 治療抵抗性のメカニズムを理解することは,効果的ながん治療の開発に不可欠です.
研究 の 目的:
- 化学療法と放射線に対する乳がん耐性を媒介するストロマ通信の役割を明らかにする.
- ストロマ媒介による治療に対する抵抗に関与する特定のシグナル伝達経路を特定する.
主な方法:
- ストロマおよび乳がん細胞間のパラクリンおよびユクスタクリンシグナリングを調査した.
- 分析されたエクソソームの移転とそのRNA含有量.
- RIG-I,STAT1,NOTCH3経路の活性化を研究した.
- ヒトとマウスの原発性乳がんモデルを利用した.
- ガンマ分泌酵素阻害剤との併用療法の有効性を評価した.
主要な成果:
- ストロマル細胞は,非コーディングRNAと移植可能な要素を含むエクソソームを乳がん細胞に転送する.
- エクソソーム由来RNAは,RIG-IとSTAT1に依存した抗ウイルスシグナリングを活性化します.
- ストロマ細胞は,乳がん細胞のNOTCH3信号伝達を活性化します.
- STAT1はNOTCH3の転写応答を強化し,治療に抵抗する腫瘍を誘発する細胞を拡張する.
- 抗ウイルス経路とNOTCH3経路は,乳がんにおけるストロマ媒介性耐性において重要である.
結論:
- ストロマル細胞は,乳がん細胞との複雑なクロストラックをエクソソームを通してオーケストラし,抗ウイルス信号伝達とNOTCH3活性化を誘導する.
- この相互作用は,治療に抵抗性のある乳がん亜集団の拡大を促進します.
- ガンマ分泌酵素阻害剤を含むこれらの経路を標的とした組み合わせ療法により,ストロマ媒介性耐性を取り消すことができます.
関連する概念動画
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies
9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.2K
Cancer Stem Cells and Tumor Maintenance
6.4K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.4K
Overview of Exosomes
4.0K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
4.0K


